Glenmark Pharma nets $170m from unusual CB
India’s Glenmark Pharmaceuticals printed its first convertible bond in more than a decade on Tuesday, raising $170m with an unusual offering that managed to pull in decent interest from investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: